title: Therapy of myelofibrosis (excluding JAK2 inhibitors).
abstract: Myelofibrosis shows a progressive clinical course and usually a poor, lethal prognosis. Allogeneic transplantation is an effective, potentially curable treatment approach although only a minority of patients may currently benefit from it. New effective treatment strategies are becoming available for this disease, including not only JAK2 inhibitors, but also other innovative drugs, targeting more general oncogenic mechanisms and the epigenetic control of cell proliferation and differentiation.
authors.affiliation: Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy. arambaldi@ospedaliriuniti.bergamo.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D013256:Steroids / Q000627:therapeutic use*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D013256:Steroids